Institutional Cluster

SVRA

Savara Inc
BULLISH
Impact 5/10
Horizonweeks Processed1mo ago
Institutional cluster: 5 buyers, 0 sellers (bullish)
Actionable Insight ▲ Bullish

The cluster of active managers adding positions suggests growing confidence in Savara's pipeline catalysts. Monitor upcoming clinical trial results or regulatory updates as potential triggers. The lack of insider buying tempers conviction, but the unanimous buying direction is a positive signal.

DirectionBullish
Confidencemedium
Horizonweeks
Latest settled — T+20d
SVRA ▼ -3.49% at T+20d
LONG call ✗ call lost -3.49% · α vs SPY -2.58% · entry $5.73 → $5.53
Next anchor: T+60d in 4w
Latest observation: T+38 -16.21% FF3 residual α
Entry anchored
Aug 7, 05:00 PM ET
via 1-min bar
T+1d
-2.79%
call -2.79% · α -2.47%
$5.57
settled 8w ago
T+5d
-6.28%
call -6.28% · α -6.24%
$5.37
settled 7w ago
T+20d
-3.49%
call -3.49% · α -2.58%
$5.53
settled 28d ago
T+60d
—
call — · α —
—
in 4w

Executive Summary

Five institutional investors, including Citigroup and Russell Investments Group, significantly increased their positions in Savara Inc (SVRA) during Q2 2026, with net buying of $1.9M. No sellers were reported, indicating growing institutional conviction in the company's pharmaceutical pipeline.

Key Financial Metrics

Direction
accumulating
Buy Value
$3.4M
Sell Value
$0.00
Net Flow
$1.9M

Institutional Positions

Net institutional flow: $1.9M

▲ Buyers (5)

InstitutionActionChangePosition ValueValue Δ
CitigroupDOUBLED+395.1%$985.0K$809.0K
State Of New Jersey Common Pension Fund DADD+26.2%$184.0K$55.0K
Walleye CapitalADD+27.5%$1.5M$467.0K
Russell Investments GroupDOUBLED+736.4%$556.0K$497.0K
Arizona State Retirement SystemADD+34%$157.0K$53.0K

Key Facts

  • 5 buyers, 0 sellers in Q2 2026 institutional cluster
  • Citigroup doubled its stake (+395% shares, value from $176K to $985K)
  • Russell Investments Group increased by 736% (value from $59K to $556K)
  • Walleye Capital added 27.5% (value from $1.1M to $1.5M)
  • Total net institutional buying: $1.9M
  • No insider open-market buying (confluence score 16/100, divergent)

Financial Impact

Institutions accumulated $1.9M in net new positions, with total current holdings of $3.4M. This represents a small fraction of SVRA's $1.2B market cap.

institutional ownershipfloat

Risk Factors

  • 13F filings have a 45-day lag; positions may have been unwound since quarter-end
  • Dollar amounts are small relative to market cap, limiting impact on float
  • No insider buying corroborates the institutional thesis

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-SVRA-2026-Q2
3 reports for SVRA
Performance horizon
Filters
Rows
Reports for SVRA — sortable, filterable
TypeNow
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$5.73 $5.53▼ −3.49%▼ −2.58%—
Jun 11, 2026
16w ago
Institutional Cluster
MIXED ★ 4/10
$5.26 $6.03▲ +14.64%▲ +12.86%—
Apr 24, 2026
22w ago
DEFA14A
NEUTRAL ★ 3/10
$5.16 $5.14▼ −0.39%▼ −5.34%—
Showing 3 of 3

US Market Status

Market Open — Closes in 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 9, 2026